Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Bioma : Berkala Ilmiah Biologi
Febiona, Keysha Putri
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Education

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Enhanced expression of L-asparaginase II by fusion of pSSPM3 synthetic promoter into pET-28a+ expression vector for alternative targeted therapy of acute lymphoblastic leukaemia Aliya, Lisana Shiddiqin; Julizar, Julizar; Rasyid, Roslaili; Pertiwi, Dian; Syukriani, Lily; Nursyafi, Fauzan Syarif; Saibi, Ihsan R. A.; Hasibuan, Imron Martua; Febiona, Keysha Putri; Jamsari, Jamsari
Bioma : Berkala Ilmiah Biologi Volume 27 Issue 2 Year 2025
Publisher : Departemen Biologi, Fakultas Sains dan Matematika, Universitas Diponegoro

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/bioma.2025.72304

Abstract

The use of commercial L-asparaginase II from E. coli and Erwinia chrysanthemi for acute lymphoblastic leukemia (ALL) therapy causes adverse effects (allergic reactions, neurotoxicity), necessitating safer alternatives. Serratia plymuthica UBCF_13, harboring the ansB gene, offers a promising source. This study constructed the recombinant plasmid pET-28a+:pSSPM3:ansB to enhance L-asparaginase II expression in E. coli using the synthetic promoter pSSPM3. Molecular verification confirmed successful steps: promoter fusion (674 bp band), ansB digestion (1,057 bp), gene insertion (1,682 bp), and BL21 transformation. Critically, enzyme activity assays revealed that pSSPM3 did not enhance expression in BL21 (0.519 U/mL), showing significantly lower activity (p<0.05) than native controls (0.621 U/mL) and DH10B transformants (0.636 U/mL). While the functional plasmid establishes a platform for novel enzyme production, the unexpected activity reduction in BL21 and higher yield in DH10B highlight host-promoter compatibility challenges. Further optimization of expression systems, purification protocols, and preclinical validation (cytotoxicity, allergenicity) are essential to advance this recombinant enzyme toward therapeutic and scalable industrial applications for ALL in resource-limited settings.
Co-Authors Aliya, Lisana Shiddiqin Dian Pertiwi Hasibuan, Imron Martua Jamsari Jamsari Julizar Julizar Lily Syukriani Nursyafi, Fauzan Syarif Roslaili Rasyid Saibi, Ihsan R. A.